{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:10:20Z","timestamp":1778537420146,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["242102311236"],"award-info":[{"award-number":["242102311236"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304286"],"award-info":[{"award-number":["82304286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82020108030"],"award-info":[{"award-number":["82020108030"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20416"],"award-info":[{"award-number":["U21A20416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117980","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:23:46Z","timestamp":1752765826000},"page":"117980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The prospects and challenges of small molecule drugs in the treatment of Duchenne muscular dystrophy"],"prefix":"10.1016","volume":"297","author":[{"given":"Yi-Ming","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Ru","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui-Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6771-9421","authenticated-orcid":false,"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Peng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117980_bib1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","article-title":"Dystrophin: the protein product of the Duchenne muscular dystrophy locus","volume":"51","author":"Hoffman","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117980_bib2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2025.117980_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.117980_bib5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib6","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/jnnp-2012-303902","article-title":"Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy","volume":"84","author":"Ricotti","year":"2013","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.ejmech.2025.117980_bib7","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1001\/jama.2022.4315","article-title":"Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"327","author":"Guglieri","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2025.117980_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-021-01758-9","article-title":"Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: can we do better?","volume":"16","author":"Kourakis","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ejmech.2025.117980_bib9","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.cgh.2022.07.032","article-title":"Comparative risk of serious infections with biologic agents and oral small molecules in inflammatory bowel diseases: a systematic review and meta-analysis","volume":"21","author":"Solitano","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.117980_bib10","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/322073a0","article-title":"Analysis of deletions in DNA from patients with becker and Duchenne muscular dystrophy","volume":"322","author":"Kunkel","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117980_bib11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD global database: analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2025.117980_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/jhg.2016.28","article-title":"Deletion of exons 3-9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy","volume":"61","author":"Nakamura","year":"2016","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2025.117980_bib13","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117980_bib14","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.cell.2008.10.018","article-title":"An ankyrin-based mechanism for functional organization of dystrophin and dystroglycan","volume":"135","author":"Ayalon","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117980_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1152\/physrev.00028.2001","article-title":"Function and genetics of dystrophin and dystrophin-related proteins in muscle","volume":"82","author":"Blake","year":"2002","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.117980_bib16","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejmech.2025.117980_bib17","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1038\/s41586-024-08310-2","article-title":"Structure and assembly of the dystrophin glycoprotein complex","volume":"637","author":"Wan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117980_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0074-7696(07)65005-0","article-title":"Biology of the striated muscle dystrophin-glycoprotein complex","volume":"265","author":"Ervasti","year":"2008","journal-title":"Int. Rev. Cytol."},{"key":"10.1016\/j.ejmech.2025.117980_bib19","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117980_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1161\/01.RES.0000126574.61061.25","article-title":"The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma","volume":"94","author":"Lapidos","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejmech.2025.117980_bib21","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1007\/s00018-021-03821-x","article-title":"Therapeutic aspects of cell signaling and communication in Duchenne muscular dystrophy","volume":"78","author":"Starosta","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117980_bib22","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.bbamem.2013.08.023","article-title":"Dystrophin complex functions as a scaffold for signalling proteins","volume":"1838","author":"Constantin","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2025.117980_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1155","article-title":"Calcium signalling: dynamics, homeostasis and remodelling","volume":"4","author":"Berridge","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117980_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.647010","article-title":"Abnormal calcium handling in Duchenne muscular dystrophy: mechanisms and potential therapies","volume":"12","author":"Mareedu","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.ejmech.2025.117980_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cvr\/cvs425","article-title":"Hierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathy","volume":"97","author":"Kyrychenko","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejmech.2025.117980_bib26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.2337\/db12-0491","article-title":"Rac1 is a novel regulator of contraction-stimulated glucose uptake in skeletal muscle","volume":"62","author":"Sylow","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2025.117980_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/antiox11040755","article-title":"The role of oxidative stress in skeletal muscle myogenesis and muscle disease","volume":"11","author":"Lian","year":"2022","journal-title":"Antioxidants"},{"key":"10.1016\/j.ejmech.2025.117980_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115664","article-title":"Oxidative stress: roles in skeletal muscle atrophy","volume":"214","author":"Zhang","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117980_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1172\/JCI36612","article-title":"Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy","volume":"119","author":"Lai","year":"2009","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117980_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.18388\/abp.2005_3458","article-title":"The involvement of oxidative stress in determining the severity and progress of pathological processes in dystrophin-deficient muscles","volume":"52","author":"Niebr\u00f3j-Dobosz","year":"2005","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ejmech.2025.117980_bib31","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/0092-8674(95)90471-9","article-title":"Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy","volume":"82","author":"Brenman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117980_bib32","doi-asserted-by":"crossref","first-page":"R1173","DOI":"10.1152\/ajpregu.00735.2009","article-title":"Regulatory interactions between muscle and the immune system during muscle regeneration","volume":"298","author":"Tidball","year":"2010","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejmech.2025.117980_bib33","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PHM.0b013e3181a5a24f","article-title":"Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy","volume":"88","author":"Evans","year":"2009","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.ejmech.2025.117980_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ejmech.2025.117980_bib35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/path.5016","article-title":"Targeting early PKC\u03b8-dependent T-cell infiltration of dystrophic muscle reduces disease severity in a mouse model of muscular dystrophy","volume":"244","author":"Lozanoska-Ochser","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.ejmech.2025.117980_bib36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ebiom.2017.01.001","article-title":"Pharmacological inhibition of PKC\u03b8 counteracts muscle disease in a mouse model of Duchenne muscular dystrophy","volume":"16","author":"Marrocco","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejmech.2025.117980_bib37","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/j.2040-4603.2018.tb00051.x","article-title":"Immunobiology of inherited muscular dystrophies","volume":"8","author":"Tidball","year":"2018","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.ejmech.2025.117980_bib38","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ejmech.2025.117980_bib39","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.bbrc.2009.11.144","article-title":"The 8th and 9th tandem spectrin-like repeats of utrophin cooperatively form a functional unit to interact with polarity-regulating kinase PAR-1b","volume":"391","author":"Yamashita","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.117980_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008411","article-title":"A Wnt-TGF\u03b22 axis induces a fibrogenic program in muscle stem cells from dystrophic mice","volume":"6","author":"Biressi","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.117980_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","article-title":"The clinical landscape for AAV gene therapies","volume":"20","author":"Kuzmin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117980_bib42","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117980_bib43","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40259-017-0234-5","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy","volume":"31","author":"Naso","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejmech.2025.117980_bib44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1038\/s41434-022-00317-6","article-title":"Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMD(mdx) rat model","volume":"29","author":"Bourdon","year":"2022","journal-title":"Gene Ther."},{"key":"10.1016\/j.ejmech.2025.117980_bib45","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s40265-023-01929-x","article-title":"Delandistrogene moxeparvovec: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117980_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/mus.27955","article-title":"Long-term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: a phase 1\/2a nonrandomized trial","volume":"69","author":"Mendell","year":"2024","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejmech.2025.117980_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1167762","article-title":"Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy","volume":"11","author":"Mendell","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.117980_bib48","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/ana.26755","article-title":"Delandistrogene moxeparvovec gene therapy in ambulatory patients (aged \u22654 to <8 years) with Duchenne muscular dystrophy: 1-year interim results from study SRP-9001-103 (ENDEAVOR)","volume":"94","author":"Zaidman","year":"2023","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib49","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1080\/14712598.2024.2394477","article-title":"The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process","volume":"24","author":"Bhattacharyya","year":"2024","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ejmech.2025.117980_bib50","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with duchenne's muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.117980_bib51","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.nmd.2023.09.008","article-title":"261st ENMC international workshop: management of safety issues arising following AAV gene therapy. 17th-19th June 2022, hoofddorp, the Netherlands","volume":"33","author":"Servais","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ejmech.2025.117980_bib52","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-024-07710-8","article-title":"Split intein-mediated protein trans-splicing to express large dystrophins","volume":"632","author":"Tasfaout","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117980_bib53","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.ymthe.2025.03.065","article-title":"The road toward AAV-Mediated gene therapy of Duchenne muscular dystrophy","volume":"33","author":"Bengtsson","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejmech.2025.117980_bib54","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/nat.2022.0063","article-title":"Next generation exon 51 skipping antisense oligonucleotides for Duchenne muscular dystrophy","volume":"33","author":"van Deutekom","year":"2023","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.ejmech.2025.117980_bib55","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/ana.23982","article-title":"Eteplirsen for the treatment of Duchenne muscular dystrophy","volume":"74","author":"Mendell","year":"2013","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib56","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41582-018-0033-8","article-title":"Why dystrophin quantification is key in the eteplirsen saga","volume":"14","author":"Aartsma-Rus","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib57","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-label evaluation of eteplirsen in patients with Duchenne muscular dystrophy amenable to exon 51 skipping: PROMOVI trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejmech.2025.117980_bib58","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117980_bib59","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1038\/mtna.2012.30","article-title":"Pip6-PMO, A new generation of peptide-oligonucleotide conjugates with improved cardiac exon skipping activity for DMD treatment","volume":"1","author":"Betts","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2025.117980_bib60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jimd.12251","article-title":"Opportunities and challenges for antisense oligonucleotide therapies","volume":"44","author":"Kuijper","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ejmech.2025.117980_bib61","doi-asserted-by":"crossref","first-page":"6244","DOI":"10.1038\/ncomms7244","article-title":"Multiplex CRISPR\/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy","volume":"6","author":"Ousterout","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117980_bib62","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117980_bib63","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.047704","article-title":"Cardiovascular phenotype of the Dmd(mdx) rat - a suitable animal model for Duchenne muscular dystrophy","volume":"14","author":"Szab\u00f3","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ejmech.2025.117980_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1602814","article-title":"CRISPR-Cpf1 correction of muscular dystrophy mutations in human cardiomyocytes and mice","volume":"3","author":"Zhang","year":"2017","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.117980_bib65","first-page":"11","article-title":"CRISPR-based therapeutic gene editing for Duchenne muscular dystrophy: advances, challenges and perspectives","author":"Chen","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117980_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70091","article-title":"Gene therapy for genetic diseases: challenges and future directions","volume":"6","author":"Qie","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2025.117980_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031832","article-title":"CRISPR therapeutics for Duchenne muscular dystrophy","volume":"23","author":"Erkut","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117980_bib68","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-scale CRISPR-mediated control of gene repression and activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2025.117980_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117980_bib70","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1038\/s41467-024-50340-x","article-title":"Adenine base editing-mediated exon skipping restores dystrophin in humanized duchenne mouse model","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117980_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for Duchenne muscular dystrophy","volume":"323","author":"Sun","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib72","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1023\/A:1025425823322","article-title":"Myoblast transplantation: the current status of a potential therapeutic tool for myopathies","volume":"24","author":"Skuk","year":"2003","journal-title":"J. Muscle Res. Cell Motil."},{"key":"10.1016\/j.ejmech.2025.117980_bib73","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ncb1542","article-title":"Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells","volume":"9","author":"Dellavalle","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.117980_bib74","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1172\/JCI81321","article-title":"Macrophages mediate cardioprotective cellular postconditioning in acute myocardial infarction","volume":"125","author":"de Couto","year":"2015","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2025.117980_bib75","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(22)00012-5","article-title":"Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"399","author":"McDonald","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2025.117980_bib76","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/JND-200556","article-title":"Mechanisms and clinical applications of glucocorticoid steroids in muscular dystrophy","volume":"8","author":"Quattrocelli","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejmech.2025.117980_bib77","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/mus.23272","article-title":"Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up","volume":"45","author":"Merlini","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ejmech.2025.117980_bib78","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.117980_bib79","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib80","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40265-023-01986-2","article-title":"Vamorolone: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117980_bib81","article-title":"A voyage on the role of nuclear factor Kappa B (NF-kB) signaling pathway in Duchenne muscular dystrophy: an inherited muscle disorder","volume":"16","author":"R","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.ejmech.2025.117980_bib82","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3233\/JND-210689","article-title":"A randomized, double-blind, placebo-controlled, global phase 3 study of edasalonexent in pediatric patients with Duchenne muscular dystrophy: results of the PolarisDMD trial","volume":"8","author":"Finkel","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.ejmech.2025.117980_bib83","article-title":"A phase 1\/2 study of flavocoxid, an oral NF-\u03baB inhibitor","volume":"11","author":"Vita","year":"2021","journal-title":"Duchenne Muscular Dystrophy, Brain Sci"},{"key":"10.1016\/j.ejmech.2025.117980_bib84","doi-asserted-by":"crossref","first-page":"H381","DOI":"10.1152\/ajpheart.00602.2003","article-title":"Inhibition and reversal of myocardial infarction-induced hypertrophy and heart failure by NHE-1 inhibition","volume":"286","author":"Chen","year":"2004","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.ejmech.2025.117980_bib85","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1139\/cjpp-2017-0265","article-title":"Na(+)-H(+) exchanger and proton channel in heart failure associated with becker and duchenne muscular dystrophies","volume":"95","author":"Bkaily","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117980_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijcard.2020.03.031","article-title":"Protective effects of rimeporide on left ventricular function in golden retriever muscular dystrophy dogs","volume":"312","author":"Ghaleh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117980_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104999","article-title":"Rimeporide as a first- in-class NHE-1 inhibitor: results of a phase Ib trial in young patients with Duchenne muscular dystrophy","volume":"159","author":"Previtali","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.117980_bib88","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1177\/0883073810371129","article-title":"Read-through strategies for suppression of nonsense mutations in Duchenne\/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124)","volume":"25","author":"Finkel","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib89","first-page":"43","article-title":"Read-through approach for stop mutations in Duchenne muscular dystrophy. An update","volume":"40","author":"Politano","year":"2021","journal-title":"Acta Myol."},{"key":"10.1016\/j.ejmech.2025.117980_bib90","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat Med"},{"key":"10.1016\/j.ejmech.2025.117980_bib91","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/1756285610388693","article-title":"Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy","volume":"3","author":"Malik","year":"2010","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.ejmech.2025.117980_bib92","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1080\/13543784.2020.1828862","article-title":"ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease","volume":"29","author":"Kerem","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejmech.2025.117980_bib93","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/cpdd.647","article-title":"Safety, tolerability, and pharmacokinetics of single ascending doses of ELX-02, a potential treatment for genetic disorders caused by nonsense mutations, in healthy volunteers","volume":"8","author":"Leubitz","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ejmech.2025.117980_bib94","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1093\/nar\/gkab194","article-title":"Effect of small molecule eRF3 degraders on premature termination codon readthrough","volume":"49","author":"Baradaran-Heravi","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.117980_bib95","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nature05756","article-title":"PTC124 targets genetic disorders caused by nonsense mutations","volume":"447","author":"Welch","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117980_bib96","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0081302","article-title":"Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy","volume":"8","author":"Finkel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117980_bib97","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-014-0287-4","article-title":"Ataluren: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117980_bib98","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054306","article-title":"Histone deacetylases: molecular mechanisms and therapeutic implications for muscular dystrophies","volume":"24","author":"Sandon\u00e0","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.117980_bib99","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1096\/fj.07-8673com","article-title":"Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice","volume":"22","author":"Nakatani","year":"2008","journal-title":"Faseb j"},{"key":"10.1016\/j.ejmech.2025.117980_bib100","doi-asserted-by":"crossref","first-page":"19183","DOI":"10.1073\/pnas.0805514105","article-title":"HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment","volume":"105","author":"Colussi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117980_bib101","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cmet.2010.07.008","article-title":"MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin\/nNOS pathway","volume":"12","author":"Cacchiarelli","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejmech.2025.117980_bib102","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(24)00036-X","article-title":"Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Mercuri","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.ejmech.2025.117980_bib103","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40265-024-02052-1","article-title":"Givinostat: first approval","volume":"84","author":"Lamb","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117980_bib104","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/339055a0","article-title":"An autosomal transcript in skeletal muscle with homology to dystrophin","volume":"339","author":"Love","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117980_bib105","first-page":"209","article-title":"Utrophin upregulation in Duchenne muscular dystrophy","volume":"24","author":"Hirst","year":"2005","journal-title":"Acta Myol."},{"key":"10.1016\/j.ejmech.2025.117980_bib106","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/cpdd.642","article-title":"A phase 1b trial to assess the pharmacokinetics of ezutromid in pediatric Duchenne Muscular Dystrophy patients on a balanced diet","volume":"8","author":"Muntoni","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.ejmech.2025.117980_bib107","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1021\/acs.jmedchem.9b01547","article-title":"Isolation, structural identification, synthesis, and pharmacological profiling of 1,2-trans-Dihydro-1,2-diol metabolites of the Utrophin modulator ezutromid","volume":"63","author":"Chatzopoulou","year":"2020","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T21:21:14Z","timestamp":1778534474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":107,"alternative-id":["S0223523425007457"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117980","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The prospects and challenges of small molecule drugs in the treatment of Duchenne muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117980"}}